Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Executive Changes

AirXpanders Installs New CFO/COO

This article was originally published in Clinica

  • News

Executive Summary

Scott Murcray has joined tissue expander specialist AirXpanders as chief financial officer/ chief operating officer, as the company is set to grow its operations beyond Australia and into the US. Murcray brings over 20 years of financial experience to AirXpanders, and has held senior finance and management roles at Nanometrics, Zoll Medical, and VNUS Medical Technologies. His appointment was announced together with news that AirXpanders had raised $20m in additional capital through a private placement. The Australia Stock Exchange-listed company will used the proceeds to grow sales of its AeroForm tissue expander in Australia, as well as to support the US launch of the product pending FDA clearance. The firm anticipates the launch to take place in 2017.

Table

View full table

Topics

Tags:
Executive Changes
Latest Headlines

CDRH’s AR/VR Home Space Will Serve As An ‘Idea Lab’ For Device Stakeholders

Digital Health Roundup: US FDA’s ‘Idea Lab’; Philips’ Roy Jakobs On AI Draft Framework; Apple Watch

EU Regulatory Roundup, April 2024: EU On Cusp Of Regulatory Shifts Amidst Political Change

Abbott Receives FDA Approval For Esprit BTK Drug-Eluting Resorbable Scaffold

See All
UsernamePublicRestriction

Register

MT103497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By